Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Launches Rituxan Rival In US

As Company Reflects On Future Of Biosimilars In US

Executive Summary

Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.

You may also be interested in...



Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma

Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.

Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021

Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.

Amgen’s Mvasi Biosimilar Overtakes Avastin In The US

Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;